malignancies, however, its impact on muscle mass in MIUC patients is undefined. As neoadjuvant chemotherapy (NC) prior to radical cystectomy is the current standard of care in MIUC, our objective was to describe preoperative changes in body composition in patients receiving platinum-based NC.
PD62-09 PATHOLOGICAL EXAMINATION EXTEMPORARY OF LYMPH NODES USING FROZEN SECTION (FS) DURING RADICAL CYSTECTOMY (RC) IS USEFUL TO SELECT PATIENTS WHO NEED SUPER EXTENDED LYMPH NODE DISSECTION (SE-LAD) : RESULTS OF A PROSPECTIVE STUDY
Maurizio Brausi*, Giancarlo Peracchia, Giuseppe De Luca, Carpi, Italy INTRODUCTION AND OBJECTIVES: The value of extemporary pathological examination of lymph nodes during RC using FS has been debated and is still controversial. In the majority of tertiary centers an extended or super-extended lymphadenectomy(E-SE-LAD) without intra-op evaluation of the nodes is performed. However this approach has drawbacks: 1. longer time of surgery 2. possible higher complication rate . To prevent this an intra-op path evaluation of the nodes removed can help in reducing the extent and time of surgery and complications. The objective of the study was to evaluate the path diagnosis on FS of lymph nodes during RC and to compare it to the final path report. Finally the impact of FS results on the extent of surgery was analized.
METHODS: The last 74 patients who received RC with ELAD for TCC of the bladder at our center were included. Obturator, internal, external, common, pre-sacral and perivesical nodes were removed bilaterally before RC and sent immediately for FS. When 1 pos. node was detected LAD was extended to the aortic bifurcation bilaterally . If none or more than 1 node was pos. at FS LAD was stopped. Mean age was 63.5 year (58-78) . Male/female ratio was : 51/23. 148 LADs were performed and nodes sent in separate containers (pelvic:obturator + internal , external, common iliac , pre-sacral,peri-vesical) for FS during RC. Pathological preparation An established path protocol for extemporary diagnosis was followed in all cases. It consisted of different passages: 1. freezing (cryostat) 2. first staining (hematossilin-Eosin) 3. cutting (5 nm thickness sections) 4. quick re-staining with hematossilin-Eosin 5. reading. RESULTS: The median N of nodes sent for FS was 18 from each side (36 in total) . 14/74 pts (19%) had pos. nodes at FS and all were confirmed at the final path evaluation . 3/14 pts. had only one pos. node (2 R, 1 L) and LAD was extended to the aortic bifurcation. The final path report confirmed the FS report and no further pos.nodes were detected. In one case (1/148 LADs) a node was suspicious at FS and pos. at the final path report: patient received ELAD. 10/14 pts. had more than one pos node: LAD was not extended further. The concordance between FS and final path report was 99.3% (147/148 LADs). In 2 patients the N of pos nodes at the final path examination was greater than the one found on FS (+ 5 and + 2). In both cases surgery was not changed.
CONCLUSIONS: A high concordance between intra-op FS diagnosis of lymph nodes and final path report was observed (99.3%). In 4% of patients (3/74) the surgical procedure was changed (ELND) due to the FS results. In 96% of our pts. an extended surgery was not necessary . FS resulted a valuable method for the detection of pos. nodes during RC. A well defined and strict path protocol and path/uro cooperation is the key. INTRODUCTION AND OBJECTIVES: Although survival benefit of cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer has been demonstrated, a significant proportion of patients do not respond. Identification of chemoresponsive cohorts would avoid morbidity and prevent delayed surgical intervention in patients who are unlikely to benefit. We evaluate the role of miRNA and mRNA expression profiles in initial TURBT specimens of patients who receive neoadjuvant chemotherapy prior to radical cystectomy. Differences in TURBT specimen expression patterns between complete responders (pT0) and nonresponders (pT2) at time of cystectomy may help stratify patients for possible neoadjuvant chemotherapy.
Source of
METHODS: FFPE tissue was isolated from initial TURBT specimens of patients with clinically localized MIBC treated with cisplatin-based neoadjuvant chemotherapy. Tissue from 9 patients with T2 disease was compared with samples from 10 pT0 patients at time of cystectomy. Differential expression of 754 miRNAs and mRNA was analyzed utilizing RT-qPCR. miRNA expression profiles were compared between complete responders and nonresponders. mRNA in tumor specimens was sequenced from both groups with 76 base pair pairedend reads using NextSeq technology. KEGG Pathway analyses were used to identify differential gene expression patterns between the two groups.
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THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 RESULTS: Significant upregulation of miRNA 485-3p, miRNA 520d, miRNA 410, miRNA 872, and miRNA 1304 was observed in nonresponders versus complete responders. KEGG pathway analysis revealed significant upregulation of the hsa03430 pathway, implicated in DNA mismatch repair, the hsa03420 pathway, implicated in nucleotide excision repair, and the hsa03410 pathway, involved in base excision repair, among pT0 patients.
CONCLUSIONS: Differential miRNA and mRNA expression within the initial tumor specimen of patients with complete pathologic regression versus progression indicates a possible role in determiningneoadjuvant chemo-sensitivity. Upregulation of DNA repair mechanisms in the primary tumor may signify chemo-sensitivity and help stratify MIBC patients being considered for neoadjuvant chemotherapy.
Source of Funding: None

PD62-11 PREDICTIVE ROLE OF EPITHELIAL TUMOR MARKER LEVEL ELEVATION AT FOLLOW-UP FOR TUMOR RECURRENCE AND ONCOLOGICAL OUTCOMES IN UROTHELIAL BLADDER CANCER
Soroush T Bazargani*, Hooman Djaladat, Anne Schuckman, Gus Miranda, Jie Cai, Sarmad Sadeghi, Tanya Dorff, David Quinn, siamak Daneshmand, Los Angeles, CA INTRODUCTION AND OBJECTIVES: We have previously reported that elevated pre-cystectomy serum levels of epithelial tumor markers (TM) and lack of TM response to neoadjuvant chemotherapy (NAChT) are associated with worse oncological outcome in patients with invasive urothelial bladder cancer (UBC). Herein, we evaluate elevation of TM levels during follow-up and their predictive role in tumor recurrence.
METHODS: Under IRB approval, serum levels of Carbohydrate Antigen 125 (CA-125), Carbohydrate Antigen 19-9 (CA 19-9) and Carcinoembryonic Antigen (CEA) were prospectively measured in 409 patients with invasive UBC between August 2011 and August 2016. Excluded from the study were metastatic (13), palliative or inoperable (5) cases. Markers were measured at different time points during follow-up.
RESULTS: A total of 391 cystectomy patients were included in the study with median age of 71 years and 79% males. Pathology was organ-confined in 59% and NAChT was given in 35% of population. Elevated precystectomy level of any of the tumor markers (31% of patients) was independently associated with worse RFS (p<0.001; HR¼2.81) and OS (p<0.001; HR¼3.97). After completion of cystectomy, we were able to document normal serum marker levels from 288 cases, of whom 26 patients (9%) developed tumor marker relapse later during follow up. This subset showed significantly more clinical recurrences (89% in elevated vs. 12% in stable group, RR¼ 7.41), and death (24% vs. 7%, RR¼3.4). Median time from tumor marker relapse to clinical recurrence was 46 days (IQR 0-179), and median time to mortality was 308 days (IQR 119-574). Details of tumor markers course in the 23 patients with marker relapse followed by clinical recurrence is shown in figure 1. Further Survival analysis using landmark time-point with log rank showed there is a significant difference in cancer-specific survival between the groups (median 284 vs 547 days; p¼0.01) ( Figure 2) . CONCLUSIONS: To our knowledge, this is the first pilot study showing predictive role of epithelial tumor marker for recurrence of invasive urothelial bladder cancer. Patients with marker relapse following cystectomy are at significant increased risk of recurrence and mortality. A larger, controlled study with longer follow up is needed to determine their role in predicting survival. . 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1197
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